---
title: "Aggressive NK‑cell Leukemia with HLH and Organ Failure Bridged to Allogeneic HSCT — Case Report"
id: "frontiers-in-immunology-15-case-report-fulminant-aggressive-nk-cell-leukemia-with-hemophagocytic"
canonical_url: "https://medichelpline.com/clinical-feed/frontiers-in-immunology-15-case-report-fulminant-aggressive-nk-cell-leukemia-with-hemophagocytic"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "Frontiers in Immunology"
source_url: "https://www.frontiersin.org/articles/10.3389/fimmu.2026.1994954"
published_at: "2026-10-28T00:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Aggressive NK‑cell Leukemia with HLH and Organ Failure Bridged to Allogeneic HSCT — Case Report
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/frontiers-in-immunology-15-case-report-fulminant-aggressive-nk-cell-leukemia-with-hemophagocytic
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** Frontiers in Immunology
- **Source URL:** [Original Journal Publication](https://www.frontiersin.org/articles/10.3389/fimmu.2026.1994954)
- **Published At:** 2026-10-28T00:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- The source page provided by the user contained only Frontiers website navigation and did not include the body text of the case report. Investigators, patient data, and outcomes were not present on the supplied page. - The original article title referenced **aggressive NK‑cell leukemia**, concurrent **hemophagocytic lymphohistiocytosis (HLH)**, multiple organ dysfunction, and bridging to **allogeneic hematopoietic stem cell transplantation (HSCT)**. The source did not present clinical timelines, laboratory trends, or imaging. - No treatment regimens, dosing, or conditioning protocols were reported on the provided page; therefore specific chemotherapy or immunosuppressive interventions cannot be summarized. - The source did not include explicit diagnostic criteria, biopsy, immunophenotyping, molecular testing, or EBV status; those data are unavailable for interpretation. - Outcomes and follow‑up details after HSCT (engraftment, graft‑versus‑host disease, survival status) were not reported in the supplied content. - Adverse events, organ‑support measures (ventilation, vasopressors, renal replacement therapy), and ICU course were not documented on the provided page. - Because the document excerpt lacks core methodology and results, readers should consult the full Frontiers in Immunology article for definitive clinical information and granular case data.
## Clinical Analysis & Structured Key Points
Frontiers | Case Report: Fulminant aggressive NK-cell leukemia with hemophagocytic lymphohistiocytosis and multiple organ dysfunction successfully bridged to allogeneic hematopoietic stem cell transplantation CASE REPORT article Front. Immunol. , 28 October 2026 Sec. Cancer Immunity and Immunotherapy Volume 17 - 2026 | https://doi.org/10.3389/fimmu.2026.1994954 Published in Frontiers in Immunology Cancer Immunity and Immunotherapy 7 impact factor 11.3 citescore Editor & Reviewers Edited by X P Xavier Poiré Reviewed by J S Jan Storek L H Lusine Harutyunyan Outline Figures and Tables Figure 1 View in article Table 1 Flow cytometric analysis of the bone marrow. View in article Table 2 Timeline of the clinical course. View in article CASE REPORT article Front. Immunol. , 28 October 2026 Sec. Cancer Immunity and Immunotherapy Volume 17 - 2026 | https://doi.org/10.3389/fimmu.2026.1994954 Case Report: Fulminant aggressive NK-cell leukemia with hemophagocytic lymphohistiocytosis and multiple organ dysfunction successfully bridged to allogeneic hematopoietic stem cell transplantation S L Shutan Li 1,2 C F Chao Fang 3 * 1. Department of Hematology, the Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China 2. Stem Cell Immunity and Regeneration Key Laboratory of Luzhou, Southwest Medical University, Luzhou, Sichuan, China 3. Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Hospital of Traditional Chinese Medicine of Southwest Medical University, Luzhou, Sichuan, China See more Article metrics View details Abstract Aggressive natural killer-cell leukemia (ANKL) is an exceedingly rare and rapidly fatal malignancy of mature NK cells, frequently associated with Epstein-Barr virus (EBV), and its diagnosis is often complicated by hemophagocytic lymphohistiocytosis (HLH) that can obscure the underlying malignancy and delay therapy. We report the case of a 28-year-old male who presented with high-grade fever, pancytopenia, hepatosplenomegaly, and disseminated intravascular coagulation (DIC), with laboratory findings confirming HLH; bone marrow examination and flow cytometry identified an aberrant NK-cell population with a characteristic immunophenotype (CD2+, sCD3−, CD56+, CD16−), establishing the diagnosis of ANKL, and next-generation sequencing revealed mutations in JAK1, ASXL1, KMT2D, and FAS. The patient received sequential multimodal therapy, including a single administration of etoposide plus dexamethasone for initial HLH control, followed by two cycles of P-Gemox (pegaspargase, gemcitabine, oxaliplatin), and subsequently underwent successful haploidentical allogeneic hematopoietic stem cell transplantation (allo-HSCT) from his sibling, followed by one year of chidamide maintenance. Complete remission was achieved after P-Gemox induction and has been maintained with full donor chimerism at 35 months of follow-up. This case highlights that timely diagnosis and a sequential, multimodal treatment strategy can successfully bridge ANKL patients presenting with HLH to curative allo-HSCT. P-Gemox appeared to be well tolerated in our patient, and these findings underscore the critical importance of early recognition and prompt treatment initiation for improving outcomes in this devastating disease. Introduction Aggressive natural killer-cell leukemia (ANKL) is a rare but devastating hematological malignancy characterized by the systemic proliferation of mature natural killer (NK) cells ( 1 ). ANKL is frequently associated with Epstein-Barr virus (EBV) infection and carries a dismal prognosis, with a median overall survival (OS) typically measured in weeks to months ( 2 , 3 ). The disease is notoriously difficult to diagnose, not only due to its rarity but also because its clinical presentation is highly non-specific and often mimics severe infections or other hematologic conditions ( 4 ). A particularly challenging aspect of ANKL is its frequent association with hemophagocytic lymphohistiocytosis (HLH), a hyperinflammatory syndrome driven by uncontrolled activation of macrophages ( 5 ). HLH can be the initial manifestation of ANKL in over 50% of cases, and its cytokine storm often dominates the clinical presentations, masking the underlying ANKL and leading to diagnostic delays and rapid clinical deterioration ( 6 , 7 ). The prognosis for patients with ANKL complicated by HLH is even more grim than for those without ( 8 ). Therapeutic advances have been made with the introduction of L-asparaginase-based regimens, which leverage the deficiency of asparagine synthetase in NK cells. The SMILE (dexamethasone, methotrexate, ifosfamide, L-asparaginase, etoposide) regimen has shown superior efficacy but is associated with significant toxicity ( 9 ). P-Gemox (pegaspargase, gemcitabine, oxaliplatin) has emerged as a less toxic alternative with comparable efficacy in NK/T-cell lymphomas ( 10 ). Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only potentially curative approach, with recent studies demonstrating improved survival in transplanted patients ( 11 , 12 ). Herein, we report a case of a young adult with ANKL presenting with severe HLH and multiorgan dysfunction who achieved complete remission with P-Gemox and successfully underwent haploidentical allo-HSCT. We also provide a comprehensive review of the literature focusing on molecular pathogenesis and therapeutic strategies. Although individual components of this management strategy have been described previously, this case is notable for the extreme severity of the initial presentation, with fulminant HLH and multiple organ dysfunction, and for the detailed longitudinal molecular and imaging follow-up, including serial PET-CT and post-transplant clearance of somatic variants. This case may therefore help inform the recognition and management of similarly affected patients. Case presentation Patient presentation and initial evaluation A 28-year-old male presented with a 5-month history of skin petechiae and ecchymoses. He was initially treated with prednisone at a local hospital. Four months prior to admission, he developed persistent high-grade fever (peak 41 °C), accompanied by dizziness, fatigue, occasional blurred vision, chest tightness, and dry cough. At the local hospital, he was diagnosed with viral myocarditis, heart failure, pulmonary infection, anemia, thrombocytopenia, and hepatic dysfunction. Due to lack of response to treatment, he was transferred to our institution’s cardiology department. Given the suspected diagnosis of hemophagocytic lymphohistiocytosis (HLH), the patient was referred to the Department of Hematology for further management. The patient had no prior history of hematological malignancies, autoimmune diseases, or chronic infections, and no history of chemotherapy or radiotherapy. He denied tobacco and alcohol use and had no known occupational exposure to leukemogens. There was no family history of hematological malignancies or hereditary diseases. On admission, vital signs were: temperature 39.8 °C, heart rate 132 bpm, respiratory rate 28/min, and blood pressure 88/51 mmHg. The patient was acutely ill with poor mental status and lethargy, and his Glasgow Coma Scale score was 13. Skin and scleral icterus were present, with scattered ecchymoses and petechiae on all extremities. A palpable left supraclavicular lymph node of approximately 1 cm was noted. The abdomen was distended with muscle guarding, tenderness, and rebound tenderness. The liver was palpable 1 cm below the right costal margin, and the spleen was palpable 3 cm below the left costal margin. Bilateral lower extremity edema was present. Laboratory findings Laboratory evaluation at admission revealed severe pancytopenia: WBC 0.51 × 10 9 /L (reference range, 3.5–9.5×10 9 /L), NEU 0.45 × 10 9 /L (reference range, 1.8–6.3×10 9 /L), HB 61 g/L (reference range, 130–175 g/L), and PLT 1 × 10 9 /L (reference range, 125–350×10 9 /L). Biochemical tests showed significant hepatic dysfunction: AST 175.2 U/L (reference range, 0–40 U/L), ALB 21.6 g/L(reference range, 40–55 g/L), TBIL 114.8 μmol/L (reference range, 3.4–20.5 μmol/L), DBIL 71.9 μmol/L (reference range, 0–6.8 μmol/L), ALP 865.1 U/L (reference range, 45–125 U/L), and LDH 797.2 U/L (reference range, 120–250 U/L). Triglycerides were markedly elevated at 14.85 mmol/L (reference range, 15%) as measured by a flow cytometry-based NK cell cytotoxicity assay (CD107a degranulation). Ferritin exceeded 1000 ng/mL (reference range, 30–400 ng/mL). Troponin T was 0.015 μg/L (reference range, 80%), supporting ANKL. Flow cytometry identified an aberrant NK-cell population comprising 2.06% of nucleated cells, and the immunophenotype was consistent with ANKL: positive for CD2, cytoplasmic CD3 (cCD3), CD56, and negative for surface CD3 (sCD3), CD4, CD5, CD8, and CD57 ( Table 1 ). The apparent discrepancy between focal CD4 positivity on immunohistochemistry and CD4 negativity on flow cytometry likely reflects differences in antibody clones, gating strategies, and the small size of the abnormal population; the flow cytometric result was considered definitive for the diagnostic immunophenotype. Figure 1 The bone marrow and PET-CT findings supported the diagnosis of ANKL. (A) Bone Marrow Aspirate. Markedly hypercellular; 19.5% unclassifiable cells with enlarged bodies, abundant cytoplasm containing vacuoles and granules, irregular eccentric nuclei, coarse chromatin, and rare nucleoli. (B) Bone Marrow Biopsy. Hypercellular (cellularity ~80%, fat ratio 4:1) with CD3ϵ + /CD56 + /EBER + lymphoid aggregates, supporting ANKL. Immunohistochemistry: CD3ϵ + , CD56(partial + ), TIA-1 + , Granzyme B + , CD30 + , P53(mutant), Ki67(70%), CD4(focal + ), CD8(scattered + ); CD5 − , CD20 − , CD7 − , CD123 − , CD100 − , CD38 − . EBER-ISH >80%. (C) Pre-treatment PET-CT. Extensive lymphadenopathy with increased FDG uptake; hepatic lesions, splenomegaly, skeletal hypermetabolic foci, mesenteric/omental thickening, and left pterygoid involvement—all suggestive of lymphoma. Also noted: pulmonary micronodules, pleural effusion, pericardial effusion, ascites, and subcutaneous edema. (D) Post-2 cycles of P-Gemox PET-CT:.Significant reduction in lymphadenopathy and FDG uptake; spleen remained enlarged but metabolically inactive; mild skeletal hypermetabolism. Pulmonary micronodules with no uptake; minor fibrotic changes; post-catheter changes. Overall assessment: CR. Table 1 Parameter Result Total nucleated cells acquired 170,000 cells Mature lymphocytes/nucleated cells 5.25% CD3 + T cells/lymphocytes 89.59% CD3 + CD4 + /CD3 + CD8 + ratio 0.37 NK cells/lymphocytes 4.62% CD3 + CD57 + T cells/lymphocytes 20.71% CD3 + CD56 + cells/lymphocytes 26.04% CD19 + B cells/lymphocytes 3.91% KAPPA/LAMBDA 1.05 Abnormal cell population/nucleated cells 2.06% Positive CD2, CD56, CD38, cCD3 Negative CD4, TCRγδ, CD5, sCD3, CD16, CD57, CD45, CD45RO, CD8, CD7, LAMBDA, CD23, CD19, CD200, KAPPA, CD20, CD10 Flow cytometric analysis of the bone marrow. Flow cytometric analysis of the bone marrow revealed an aberrant NK-cell population accounting for 2.06% of nucleated cells, characterized by large cell size and high side scatter (SSC), raising suspicion for ANKL. Next-generation sequencing (NGS) revealed mutations in JAK1 (c.2108G>T, p.Ser703Ile, 11.3% variant allele frequency), ASXL1 (c.1934dup, p.Gly646TrpfsTer12, 10.1%), KMT2D (c.6040C>T, p.Gln2014Ter, 10.9%), and FAS (c.197-1G>A, 10.3%; c.355T>C, p.Cys119Arg, 10.4%). Chromosomal analysis showed a normal karyotype (46, XY). PET-CT demonstrated extensive involvement: generalized lymphadenopathy with increased FDG uptake, hepatosplenomegaly with diffuse FDG uptake, multiple bone marrow lesions with increased FDG uptake, and left pterygoid soft tissue thickening with increased FDG uptake ( Figure 1C ). Pulmonary nodules, pleural effusion, and pericardial effusion were also noted. A definitive diagnosis of ANKL with secondary HLH ( 13 ) was made. Management and transplantation The patient was initially started on etoposide (VP16) and dexamethasone to control the hyperinflammatory syndrome. Empirical broad-spectrum antibacterial and antifungal therapy was initiated, together with supportive measures including transfusions, hydration, diuretics, hepatoprotective agents, electrolyte supplementation, and oxygen therapy. Following confirmation of the diagnosis, the patient received P-Gemox chemotherapy (gemcitabine 1.6 g, oxaliplatin 160 mg, pegaspargase 3750 U). P-Gemox induction was well tolerated in this patient, with no clinically significant treatment-related toxicities observed. No dose reductions were required. The patient did not develop pancreatitis, thrombosis, or hypersensitivity reactions. A lumbar puncture was performed, with no evidence of central nervous system involvement; intrathecal chemotherapy (methotrexate 12.5 mg, cytarabine 50 mg, dexamethasone 5 mg) was administered prophylactically. After two cycles of P-Gemox, the patient achieved complete remission. Response was assessed according to standard criteria for NK/T-cell neoplasms, incorporating clinical evaluation, bone marrow morphology, flow cytometry, EBER-ISH, and PET-CT. Complete remission was defined as the absence of morphologically detectable abnormal cells on bone marrow examination, negative flow cytometric residual disease assessment, EBER negativity on bone marrow biopsy, and complete metabolic response on PET-CT (Deauville score ≤ 3). The sensitivity of flow cytometry was approximately 10 −5 , and molecular monitoring was performed by NGS with a sensitivity of approximately 1–5% variant allele frequency. Accordingly, bone marrow examination showed no abnormal cells, flow cytometry was negative for residual disease, bone marrow biopsy showed no lymphoma cells with EBER negativity, and PET-CT demonstrated significant resolution of previous lesions with markedly decreased FDG uptake ( Figure 1D ). The patient underwent haploidentical allo-HSCT from his 26-year-old brother (6/12 HLA-matched). Peripheral blood stem cells mobilized with recombinant human granulocyte colony-stimulating factor (rhG-CSF, filgrastim) were used as the graft source. Conditioning consisted of the FBA regimen (fludarabine 30 mg/m²/day on days −6 to −2, busulfan 3.2 mg/kg/day on days −5 to −4, and cytarabine 2 g/m²/day on days −6 to −3). The graft contained CD34+ cells 5.2 × 10 6 /kg and mononuclear cells 5.7 × 10 8 /kg. The patient developed sepsis (Klebsiella pneumoniae) on day +11, which was successfully managed with antibiotics. Neutrophil engraftment occurred at day +20, and platelet engraftment at day +32. For GVHD prophylaxis, rabbit anti-thymocyte globulin (Thymoglobulin) was administered at a total dose of 5 mg/kg (2.5 mg/kg/day on days −3 and −2), together with cyclosporine, mycophenolate mofetil, and prednisone. All anti-rejection medications were completely discontinued after six months. The patient then received chidamide maintenance therapy for one year. Post-transplant follow-up At the two-month post-transplant evaluation, blood counts and liver function had normalized. EBV DNA was negative, while CMV was detectable at 3.896×10³ copies/mL and was treated with ganciclovir. The patient was negative for JAK1, ASXL1, KMT2D, and FAS mutations. Chimerism analysis showed 99.66% donor cells. There was no evidence of acute GVHD. At six months post-transplantation, EBV became undetectable, and all anti-rejection medications were completely discontinued. Chidamide maintenance therapy was continued for one year and was completed without significant adverse events or dose reductions. No grade 3–4 adverse events, unexpected events, or treatment-related hospitalizations occurred during maintenance. The patient underwent regular follow-up with a total of six lumbar punctures and intrathecal chemotherapy administrations. At 35 months of follow-up after HSCT, the patient was doing well and remained in complete remission (CR). A detailed timeline of the clinical course, including key diagnostic and therapeutic milestones, is presented in Table 2 . Table 2 Phase Time point Event Presentation & diagnosis Onset Skin petechiae and ecchymoses Local hospital Misdiagnosed as viral myocarditis Referral to our institution Diagnosis of HLH Bone marrow/flow cytometry/NGS Diagnosis of ANKL Initial treatment VP16 + dexamethasone Control of HLH P-Gemox cycles 1–2 Induction therapy Response evaluation CR (PET-CT, bone marrow, EBER) Transplantation Haploidentical allo-HSCT FBA conditioning Day +11 Klebsiella pneumoniae sepsis Day +20 Neutrophil engraftment Day +32 Platelet engraftment Follow-up 2 months Chimerism 99.66%, EBV negative, CMV positive 6 months EBV undetectable, discontinuation of anti-rejection medications 1 year Completion of chidamide maintenance 35 months Sustained CR Timeline of the clinical course. Key diagnostic and therapeutic milestones are summarized, including initial presentation, referral, diagnosis of ANKL with HLH, etoposide plus dexamethasone, P-Gemox induction, complete remission, haploidentical allo-HSCT, engraftment, post-transplant complications, chidamide maintenance, and durable remission at 35 months. HLH, hemophagocytic lymphohistiocytosis; ANKL, aggressive NK-cell leukemia; NGS, next-generation sequencing; CR, complete remission; allo-HSCT, allogeneic hematopoietic stem cell transplantation; FBA, fludarabine + busulfan + cytarabine; EBV, Epstein–Barr virus; CMV, cytomegalovirus. Discussion The diagnosis of ANKL complicated by HLH poses a significant challenge, particularly for non-hematology specialists. HLH can be triggered by infections (especially EBV) or malignancies, making it essential to exclude underlying cancer ( 14 ). ANKL is frequently associated with HLH and carries a dismal prognosis ( 15 ). Our patient’s favorable outcome was attributable to timely diagnosis. Therefore, ANKL should be a leading differential in patient presenting with HLH, especially when EBV viremia and rapid deterioration are present. A definitive diagnosis of ANKL requires a multimodal approach. While bone marrow aspirate may reveal large granular lymphocytes, it lacks specificity ( 16 ). Flow cytometry is the cornerstone, s
## Related Clinical Research

- [Transjugular Liver Biopsy–Confirmed Lymphoma Presenting as HLH With Severe Thrombocytopenia: Case](https://medichelpline.com/clinical-feed/frontiers-in-immunology-12-case-report-transjugular-liver-biopsy-confirmed-lymphoma-presenting-as.md)
- [Angioimmunoblastic T‑cell Lymphoma Complicated by Secondary HLH Initially Misdiagnosed as Classica](https://medichelpline.com/clinical-feed/pubmed-42826277.md) (DOI: 10.1097/MD.0000000000050979)
- [LIF-Engineered Mesenchymal Stromal Cells Reduce Mortality and Reprogram Cytokines in LPS Endotoxem](https://medichelpline.com/clinical-feed/pubmed-42969209.md) (DOI: 10.1111/1348-0421.70102)
- [Soft palate length, thickness, and volume in bulldogs after staphylectomy versus folded-flap palat](https://medichelpline.com/clinical-feed/plos-one-19-a-comparison-of-soft-palate-thickness-length-and-volume-in-bulldogs-before-and.md)
- [Preserved aerobic capacity after allogeneic HCT in an elite endurance runner](https://medichelpline.com/clinical-feed/frontiers-in-immunology-16-case-report-running-through-transplant-preserved-aerobic-capacity-in-an-elite.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.